BioSpace News Archive

The company teased data for efinopegdutide, a GLP-1/glucagon receptor co-agonist, in nonalcoholic steatohepatitis compared to Novo Nordisk’s semaglutide, which is not yet approved for NASH.

The pendulum has swung back in favor of employees, and employers are struggling to retain employees as workers become less engaged.

The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.

The biotech company is collaborating with Israel’s NeuroSense to study how the latter’s amyotrophic lateral sclerosis candidate affects plasma neurofilament levels in patients.

See inside for the top 20 biopharma companies with the most significant gaps in pay between their chief executives and median employees.

Jubilant Therapeutics’ differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.

The biopharma company’s plan to issue and sell $100 million of shares of its common stock comes just days after releasing late-breaking Phase I/II data for menin inhibitor ziftomenib.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities observed.

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, announced that it recently launched a funding round of up to $10 million.

Gilead Sciences, Inc. announced new data to be presented at the European Association for the Study of the Liver Congress 2023, June 21-24, 2023.